Community Research and Development Information Service - CORDIS


CelSys Shock Report Summary

Project ID: 328796
Funded under: FP7-PEOPLE
Country: Italy

Periodic Report Summary 1 - CELSYS SHOCK (Autodigestion in Hemorrhagic Shock and Acute Heart Failure: a Cell-to-System Approach to Pathophysiology and Therapy)

The main objective of the “CelSys Shock” project is to shed light on the relationship between the fundamental mechanisms of circulatory shock, and acute heart failure. To achieve such a goal, a multiscale approach to the study of the effects of shock will entail the generation and integration of data at molecular level, cellular level, and organ and system level. In parallel with the investigation of the main features of shock and its effects on cardiovascular function, the project will deal with the development of an innovative therapeutic approach for the prevention of heart dysfunction and multiple organ failure in the context of circulatory shock.
The results achieved during the first year of the CelSys shock project have mainly shown that the extent of heart injury needs to be carefully evaluated from different angles. In particular, the analysis of the potential malfunction of several receptors in the heart is being currently carried out (alpha1, beta2, FATP, CD36, hFABP, insulin receptor). Preliminary results have already demonstrated that the activity of MMP2, MMP9, and serine proteases in the heart is elevated during hemorrhagic shock, and an adequate therapy consisting in the administration of a protease inhibitor in the lumen of the intestine is able to significantly reduce this activity. The analysis of the proteolytic damage induced by these enzymes is currently under way.
In parallel, an innovative technology for the safe delivery of protease inhibitor in the intestine, via an oral catheter has been the object of a new invention, for which a disclosure has been filed with the University of California San Diego Technology Transfer and Intellectual Property Services.
The long-term objectives of the project, i.e. the development of a viable therapeutic approach for the timely treatment of acutely ill shock patients in the intensive care unit, will be pursued during the second year of the CelSys Shock project, by means of the refinement of the newly designed technology. The impact of this approach could be of the utmost importance in improving the survival expectancy of shock patients.


Fabio Conti, (Chief financial officer)
Tel.: +39 02 23993431
Fax: +390223993417


Life Sciences
Record Number: 184249 / Last updated on: 2016-06-07
Information source: SESAM
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top